Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 44

1.

Reduction of the dose of radiotherapy to the elective neck in head and neck squamous cell carcinoma; a randomized clinical trial. Effect on late toxicity and tumor control.

Nevens D, Duprez F, Daisne JF, Dok R, Belmans A, Voordeckers M, Van den Weyngaert D, De Neve W, Nuyts S.

Radiother Oncol. 2016 Aug 12. pii: S0167-8140(16)34247-5. doi: 10.1016/j.radonc.2016.08.009. [Epub ahead of print]

PMID:
27528118
2.

A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378).

Tryfonidis K, Basaran G, Bogaerts J, Debled M, Dirix L, Thery JC, Tjan-Heijnen VC, Van den Weyngaert D, Cufer T, Piccart M, Cameron D; EORTC-Breast Cancer Group.

Eur J Cancer. 2016 Jan;53:144-54. doi: 10.1016/j.ejca.2015.10.012. Epub 2015 Dec 24.

PMID:
26724641
3.

Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-Analysis.

Vanderveken OM, Szturz P, Specenier P, Merlano MC, Benasso M, Van Gestel D, Wouters K, Van Laer C, Van den Weyngaert D, Peeters M, Vermorken J.

Oncologist. 2016 Jan;21(1):59-71. doi: 10.1634/theoncologist.2015-0246. Epub 2015 Dec 28.

PMID:
26712958
4.

Evaluation of the optimal combinations of modulation factor and pitch for Helical TomoTherapy plans made with TomoEdge using Pareto optimal fronts.

De Kerf G, Van Gestel D, Mommaerts L, Van den Weyngaert D, Verellen D.

Radiat Oncol. 2015 Sep 17;10:191. doi: 10.1186/s13014-015-0497-2.

5.

Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab.

Szturz P, Specenier P, Van Laer C, Van Den Weyngaert D, Corthouts B, Carp L, Van Marck E, Vanderveken O, Vermorken JB.

Eur Arch Otorhinolaryngol. 2016 Jun;273(6):1629-36. doi: 10.1007/s00405-015-3673-y. Epub 2015 Jun 5.

PMID:
26044403
6.

Helical tomotherapy in head and neck cancer: a European single-center experience.

Van Gestel D, Van den Weyngaert D, De Kerf G, De Ost B, Vanderveken O, Van Laer C, Specenier P, Geussens Y, Wouters K, Meulemans E, Cheung KJ, Grégoire V, Vermorken JB.

Oncologist. 2015 Mar;20(3):279-90. doi: 10.1634/theoncologist.2014-0337. Epub 2015 Feb 11.

7.

Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.

Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, Schinagl D, Oei B, Rodenhuis C, Horiot JC, Struikmans H, Van Limbergen E, Kirova Y, Elkhuizen P, Bongartz R, Miralbell R, Morgan D, Dubois JB, Remouchamps V, Mirimanoff RO, Collette S, Collette L; European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups.

Lancet Oncol. 2015 Jan;16(1):47-56. doi: 10.1016/S1470-2045(14)71156-8. Epub 2014 Dec 9. Erratum in: Lancet Oncol. 2015 Jan;16(1):e6.

PMID:
25500422
8.

The radiosensitising effect of gemcitabine and its main metabolite dFdU under low oxygen conditions is in vitro not dependent on functional HIF-1 protein.

Wouters A, Pauwels B, Burrows N, Baay M, Deschoolmeester V, Vu TN, Laukens K, Meijnders P, Van Gestel D, Williams KJ, Van den Weyngaert D, Vermorken JB, Pauwels P, Peeters M, Lardon F.

BMC Cancer. 2014 Aug 16;14:594. doi: 10.1186/1471-2407-14-594.

9.

Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response.

Boeckx C, Weyn C, Vanden Bempt I, Deschoolmeester V, Wouters A, Specenier P, Van Laer C, Van den Weyngaert D, Kockx M, Vermorken JB, Peeters M, Pauwels P, Lardon F, Baay M.

BMC Res Notes. 2014 Jun 4;7:337. doi: 10.1186/1756-0500-7-337.

10.

HPV-related oropharyngeal cancers in Flanders (Belgium): a multicenter study.

Van Limbergen EJ, Dok R, Laenen A, Hauben E, Van den Weyngaert D, Voordeckers M, De Neve W, Duprez F, Nuyts S.

B-ENT. 2014;10(1):7-14.

PMID:
24765823
11.

An international phase 3 trial in head and neck cancer: quality of life and symptom results: EORTC 24954 on behalf of the EORTC Head and Neck and the EORTC Radiation Oncology Group.

Bottomley A, Tridello G, Coens C, Rolland F, Tesselaar ME, Leemans CR, Hupperets P, Licitra L, Vermorken JB, Van Den Weyngaert D, Truc G, Barillot I, Lefebvre JL.

Cancer. 2014 Feb 1;120(3):390-8. doi: 10.1002/cncr.28392. Epub 2013 Oct 25.

12.

Reduction of the dose to the elective neck in head and neck squamous cell carcinoma, a randomized clinical trial using intensity modulated radiotherapy (IMRT). Dosimetrical analysis and effect on acute toxicity.

Nuyts S, Lambrecht M, Duprez F, Daisne JF, Van Gestel D, Van den Weyngaert D, Platteaux N, Geussens Y, Voordeckers M, Madani I, De Neve W.

Radiother Oncol. 2013 Nov;109(2):323-9. doi: 10.1016/j.radonc.2013.06.044. Epub 2013 Aug 13.

PMID:
23953410
13.

The potential of helical tomotherapy in the treatment of head and neck cancer.

Van Gestel D, Verellen D, Van De Voorde L, de Ost B, De Kerf G, Vanderveken O, Van Laer C, Van den Weyngaert D, Vermorken JB, Gregoire V.

Oncologist. 2013 Jun;18(6):697-706. doi: 10.1634/theoncologist.2012-0424. Epub 2013 May 30.

14.

RapidArc, SmartArc and TomoHD compared with classical step and shoot and sliding window intensity modulated radiotherapy in an oropharyngeal cancer treatment plan comparison.

Van Gestel D, van Vliet-Vroegindeweij C, Van den Heuvel F, Crijns W, Coelmont A, De Ost B, Holt A, Lamers E, Geussens Y, Nuyts S, Van den Weyngaert D, Van den Wyngaert T, Vermorken JB, Gregoire V.

Radiat Oncol. 2013 Feb 20;8:37. doi: 10.1186/1748-717X-8-37.

15.

The intriguing interplay between therapies targeting the epidermal growth factor receptor, the hypoxic microenvironment and hypoxia-inducible factors.

Wouters A, Boeckx C, Vermorken JB, Van den Weyngaert D, Peeters M, Lardon F.

Curr Pharm Des. 2013;19(5):907-17. Review.

PMID:
22973959
16.

Isolated lung perfusion with gemcitabine combined with radiotherapy: no additional lung toxicity in an experimental model.

Van Thielen J, Wittock A, Hendriks J, den Hengst W, De Pooter C, Van den Weyngaert D, Pauwels P, Van Schil P.

Eur J Cardiothorac Surg. 2012 Oct;42(4):712-8. doi: 10.1093/ejcts/ezs024. Epub 2012 Feb 15.

PMID:
22345281
17.

Reference dosimetry for helical tomotherapy: practical implementation and a multicenter validation.

De Ost B, Schaeken B, Vynckier S, Sterpin E, Van den Weyngaert D.

Med Phys. 2011 Nov;38(11):6020-6. doi: 10.1118/1.3651496.

PMID:
22047366
18.

Tongue cancers during pregnancy: Case reports and review of literature.

Mhallem Gziri M, Han SN, Van Calsteren K, Heyns L, Delaere P, Nuyts S, Van den Heuvel F, Cheron AC, Fossion E, Van den Weyngaert D, Lok C, Amant F.

Head Neck. 2013 Apr;35(4):E102-8. doi: 10.1002/hed.21924. Epub 2011 Oct 19. Review.

PMID:
22009853
19.

Experimental determination of the energy response of alanine pellets in the high dose rate 192Ir spectrum.

Schaeken B, Cuypers R, Goossens J, Van den Weyngaert D, Verellen D.

Phys Med Biol. 2011 Oct 21;56(20):6625-34. doi: 10.1088/0031-9155/56/20/007. Epub 2011 Sep 23.

PMID:
21941030
20.

Intensity-modulated radiotherapy in patients with head and neck cancer: a European single-centre experience.

Van Gestel D, Van Den Weyngaert D, Schrijvers D, Weyler J, Vermorken JB.

Br J Radiol. 2011 Apr;84(1000):367-74. doi: 10.1259/bjr/67058055.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk